Merck & Company - an Opportunity to Evaluate the Licensing of a Drug

In: Business and Management

Submitted By minar
Words 320
Pages 2
Problem Definition

Should Rich Kender recommend licensing Davanrik, making Merck & Company responsible for its manufacture and its marketing?

In order to provide Rich Kender with a good and thorough analysis and recommendation on the Davanrik licensing project, we need to answer the following guidance questions:

I. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs?

II. How much should they pay?

III. What is the expected value of the licensing arrangement to LAB?

IV. How would our analysis change if the costs of launching Davanrik for weight loss were $225 million instead of $100 million?

In our analysis we will build a decision tree that shows the cash flows and probabilities at all stages of the FDA approval process. We will assume a royalty fee of 5% on the cash flows that Merck receives from Davanrik after successful launch.

Analysis

Merck is in the business of developing compounds for pharmaceutical compounds. The required research and development efforts preceding the launch of a successful blockbuster drug is extensive and lengthy process and is therefore a very expensive one. Nevertheless, Merck has proven perfectly capable to achieve high returns on capital. This is a result of numerous factors.

First of all, Merck has been able to generate tremendous amounts of sales. Since 1995, Merck has launched 15 new products, resulting in 1999 sales of $32.7 billion, which includes $15.2 billion in pharmaceutical benefit management services (PBM) sales. Some products were developed through joint ventures, allowing for a division of costs but also future revenues.

Furthermore, these new products are protected by law under patents, which give Merck the exclusive rights to the production and sales. Since Merck is then the only manufacturer of a substance,…...

Similar Documents

Drug Companies

...WESTERN DRUG COMPANIES AND THE AIDS EPIDEMIC IN SOUTH AFRICA | | | | | | | | INTRODUCTION The AIDS epidemic in South Africa is at an extreme where 4.2 million of the country’s 43 million citizens are afflicted. This translates into one in every ten citizens being infected with the virus. Additionally 34 million Sub Saharan African citizens have been afflicted and 11.5 million have died and that total accounts for 83% of the world’s AIDS related deaths. Treatment is available in the form of an anti-retroviral, but it is very costly and as such unaffordable for the already impoverished nations in Africa. The AIDS crisis and the expensive treatment have caused the government of South Africa to pass laws authorising the practice of parallel importing and compulsory licensing. Parallel importing allows importers to purchase the medication from the cheapest source whether or not the patent holders gave approval and compulsory licensing allows the government to license local companies to produce cheaper versions of the drug patented by foreign companies with or without their consent. The passing of the law by the South African government caused a legal dispute with the US drug companies regarding intellectual property rights, compulsory licensing and parallel importing. The dispute caused a debate among public health officials, activists, law makers and the drug companies over the importance of public health versus corporate profits and the bad public......

Words: 1750 - Pages: 7

Merck & Company: Evaluating a Drug Licensing Opportunity

...Problem Definition Should Rich Kender recommend licensing Davanrik, making Merck & Company responsible for its manufacture and its marketing? In order to provide Rich Kender with a good and thorough analysis and recommendation on the Davanrik licensing project, we need to answer the following guidance questions: I. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs? II. How much should they pay? III. What is the expected value of the licensing arrangement to LAB? IV. How would our analysis change if the costs of launching Davanrik for weight loss were $225 million instead of $100 million? In our analysis we will build a decision tree that shows the cash flows and probabilities at all stages of the FDA approval process. We will assume a royalty fee of 5% on the cash flows that Merck receives from Davanrik after successful launch. Analysis Merck is in the business of developing compounds for pharmaceutical compounds. The required research and development efforts preceding the launch of a successful blockbuster drug is extensive and lengthy process and is therefore a very expensive one. Nevertheless, Merck has proven perfectly capable to achieve high returns on capital. This is a result of numerous factors. First of all, Merck has been able to generate tremendous amounts of sales. Since 1995, Merck has launched 15 new products, resulting in 1999 sales of $32.7 billion, which includes $15.2......

Words: 581 - Pages: 3

Merck & Company

...Should Rich Kender recommend licensing Davanrik, making Merck & Company responsible for its manufacture and its marketing? In order to provide Rich Kender with a good and thorough analysis and recommendation on the Davanrik licensing project, we need to answer the following guidance questions: I. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drugs? II. How much should they pay? III. What is the expected value of the licensing arrangement to LAB? IV. How would our analysis change if the costs of launching Davanrik for weight loss were $225 million instead of $100 million? In our analysis we will build a decision tree that shows the cash flows and probabilities at all stages of the FDA approval process. We will assume a royalty fee of 5% on the cash flows that Merck receives from Davanrik after successful launch. Analysis Merck is in the business of developing compounds for pharmaceutical compounds. The required research and development efforts preceding the launch of a successful blockbuster drug is extensive and lengthy process and is therefore a very expensive one. Nevertheless, Merck has proven perfectly capable to achieve high returns on capital. This is a result of numerous factors. First of all, Merck has been able to generate tremendous amounts of sales. Since 1995, Merck has launched 15 new products, resulting in 1999 sales of $32.7 billion, which includes $15.2 billion in......

Words: 315 - Pages: 2

Definition Merck Company

...of each of the three companies are; Merck: Pharmaceutical drugs, consumer medical products, Vaccines and Animal medical care products. Whole foods market: beverages, snacks, frozen foods, bakery, grocery, beer, Alcohol, body care products, Animal food products. Johnson&Johnson: Body care products, Baby care products, body Medical products, Oral hygiene products, eye medical products, Medical Devices & Diagnostics, Medical products. Merck company which sells products that are basically medical related products The company`s business is preserving and improving human life. They also work to improve animal health. The company is dedicated to the highest level of scientific excellence and commit their research to improve human and animal health and the quality of life. They strive to identify the most critical needs of consumers and customers, and they devote their resources to meeting those needs. Wholefoodsmarket Company which sells groceries, foods etc. are dedicated to providing high standards and their goal is to sell the highest quality products that they possibly can. They define quality by evaluating the ingredients, freshness, safety, taste, nutritive value and appearance of all of the products that they possess. They care for the general ware fare of their consumers, which includes, food, body care products etc. They also care for dog`s ware fare too by providing the most healthy dog food products available. Johnson&Johnson company which sells......

Words: 263 - Pages: 2

Merck and Co

...9-201-023 R E V: M A R C H 25, 2003 RI CH A R D S. R U B A CK Merck & Company: Evaluating a Drug Licensing Opportunity Rich Kender, Vice President of Financial Evaluation & Analysis at Merck, was working with his team to decide whether his company should license Davanrik, a new drug with the potential to treat both depression and obesity. The small pharmaceutical concern that developed the drug, LAB Pharmaceuticals, lacked the resources to complete the lengthy approval process, manufacture the compound, and market the drug. LAB had approached Merck with an offer to license the compound. Under this agreement, Merck would be responsible for the approval of Davanrik, its manufacture, and its marketing. The company would pay LAB an initial fee, a royalty on all sales, and make additional payments as Davanrik completed each stage of the approval process. Merck In 2000, Merck & Co., Inc. was a global research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of human and animal health products, directly and through its joint ventures, and provides pharmaceutical benefit management services (PBM) through Merck-Medco Managed Care. Since 1995, Merck had launched 15 new products including Vioxx™ for the treatment of osteoarthritis, Fosamax™ for the treatment of osteoporosis and Singulair™ for treating asthma. The Company earned $5.9 billion on 1999 sales1 of $32.7 billion, about a 20% increase from 1998. Exhibits 1 and 2 contain......

Words: 2375 - Pages: 10

Merck Drug Co

...Evaluating a Drug Licensing Opportunity Statement of the problem- Merck must determine whether or not to bid to license Davanrik My recommendation is that Merck must definitely make a competitive bid for Davanrik. The total expected value from the deal based numbers given in the Merck article is a healthy $14million so keeping a 20% incentive, Merck should bid no more than $11million for Davanrik as the initial licensing fee. Looking at the background of Merck, it is clear that it is a successful company with good cash flow and investable assets. Not only can Merck afford to take risk but also given the fact that several of its key patents are expiring in 2002, Merck must replenish its patented product portfolio otherwise Merck risks loosing its profit margins in future. Since the pharmaceutical business is based on high-risk high-reward model, Merck should be aggressive in getting new products on the market. Although Merck could be developing its own new products, Davanrik presents an interesting opportunity since the parent company LAB pharmaceuticals is eager to license the drug in light of its recent FDA rejection. Looking for a much needed cash influx, LAB might be willing to strike a bargain. To evaluate the risks/rewards of the deal we construct a decision tree for Merck. The structure of tree presents a clearer picture of the possible risks and rewards during the comprehensive FDA approval process. Looking at this decision tree in phase 3, perhaps Merck......

Words: 721 - Pages: 3

Merck

...TEACHING NOTE – Adapted From Harvard Business School MERCK & COMPANY: Evaluating a Drug Licensing Opportunity Substantive Issues The case explores the valuation of an opportunity to license a compound before it enters clinical trials and describes Merck’s decision tree evaluation process. It also provides information to evaluate a specific licensing opportunity, including the costs of the three phases of the review process, the present value of the revenues associated with successful outcomes, and the probability of various outcomes. Questions 1. How has Merck been able to achieve substantial returns to capital given the large costs and lengthy time to develop drug? 2. Build a decision tree that shows the cash flows and probabilities at all stages of the FDA approval process. 3. Should Merck bid to license Davanrik? How much should they pay? Is this the STATEMENT OF THE PROBLEM? 4. What is the expected value of the licensing arrangement to LAB? Assume a 5% royalty fee on any cash flows that Merck receives from Davanrik after a successful launch. 5. How would your analysis change if the costs of launching Davanrik for weight loss were $225 million instead of $100 million as given in the case? 6. WHAT IS YOUR RECOMMENDATION? Exhibit TN-1 Decision Alternatives |Phase I |Phase II |Phase III ......

Words: 521 - Pages: 3

Merck

...9-201-023 REV: MARCH 25, 2003 RICHARD S. RUBACK Merck & Company: Evaluating a Drug Licensing Opportunity Rich Kender, Vice President of Financial Evaluation & Analysis at Merck, was working with his team to decide whether his company should license Davanrik, a new drug with the potential to treat both depression and obesity. The small pharmaceutical concern that developed the drug, LAB Pharmaceuticals, lacked the resources to complete the lengthy approval process, manufacture the compound, and market the drug. LAB had approached Merck with an offer to license the compound. Under this agreement, Merck would be responsible for the approval of Davanrik, its manufacture, and its marketing. The company would pay LAB an initial fee, a royalty on all sales, and make additional payments as Davanrik completed each stage of the approval process. Merck In 2000, Merck & Co., Inc. was a global research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of human and animal health products, directly and through its joint ventures, and provides pharmaceutical benefit management services (PBM) through Merck-Medco Managed Care. Since 1995, Merck had launched 15 new products including Vioxx™ for the treatment of osteoarthritis, Fosamax™ for the treatment of osteoporosis and Singulair™ for treating asthma. The Company earned $5.9 billion on 1999 sales1 of $32.7 billion, about a 20% increase from 1998. Exhibits 1 and 2 contain Merck’s Income...

Words: 2360 - Pages: 10

Merck and Vioxx Drug Recall

... Case Study: Merck and the Vioxx Recall Kelvin Gabel Benedictine University Case Study: Merck and the Vioxx Recall According to Lawrence and Weber (2014), former Merck CEO George W. Merck implied a corporate vision of social responsibility for Merck & Co., Inc. (Merck) when he stated in 1950 that medicine was for the people and that loyalty to that concept would lead to greater profits. On the surface, it appears Merck has historically lived its declared mission of putting people first. This is demonstrated by the company forfeiting patent and profits from the antibiotic streptomycin and the drug Mectizan (Lawrence, 2014). Merck was well rewarded for its people first philosophy. Though it was ranked fifth in asset and market value, it ranked first in profits. Additionally the company had a stellar reputation of being perceived as the most ethical and socially responsible of the major drug companies (Lawrence, 2014). Today Merck Pharmaceutical’s mission statement is “to discover, develop and provide innovative products and services that save and improve lives around the world (Merck, 2015).” Reading Merck’s current mission statement lacks both the compassion of placing people first and the implied social responsibility of Mr. Merck’s statement in 1950. To be contextually correct historically in forming a view of Merck and the Vioxx recall issue, I sought to find a corporate mission statement from the period of the recall which was in 2006. According to......

Words: 1294 - Pages: 6

Merck & Company -Evaluating a Drug Licensing Opportunity .Doc

...INTRODUCTION Merck & Company : Evaluating the Licensing Opportunity Various recently-born biotech companies sell their technologies in either finished or early stage to bigger companies in need of financing capital to preceed business, while those bigger companies acquire technologies to scout for promising profitable business. This sort of process needs numbers of decision makings and agreements from both parties on the valuation methods is crucial here. The valuation method being used has to hold objective validity and generality. For the managers to make accurate forecast of future profitability in managing companies, quantified decision making process is needed. Here we are dealing about whether Merck should give financial support to the R&D project of Davanrik offered by LAB, and about the process of valuation and the final decision. First we are to make brief of LAB’s business proposal and practice detailed valuation functions to decide if the proposal is profitable or not. And finally we will make a decision based on the valuation process in perspective of Rich Kender, Vice President of Financial Evaluation & Analysis of Merck. Brief introduction of Merck and its agenda regarding Davanrik project As a world-class pharmaceutical company concentrated on R&Ds, Merck is performing various researches and developments upon medical supplies for human and animals. Merck is providing Pharmaceutical Benefit Management (i.e. PBM) through a company called Merck-Medco......

Words: 1134 - Pages: 5

Merck Licencesing Opportunity

...Case report Merck&Co: Evaluating a drug licensing opportunity Background The case is set in the year 2000. Merck&Co. is a global, research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of human as well as animal health products. It operates directly or through established joint ventures and provides pharmaceutical management services (PBM). During the last 5 years the company has launched 15 new successful products; the most popular drugs generated the amount of $5.7 billion in worldwide sales. Between 1998 and 1999 a 20% increase in sales was observed. Merck owns patents on their most popular drugs, however they will expire by 2002. Once the patents are expired, sales will decline when generic cheap substitutes enter the market. The company aims at maintaining a healthy pipeline in the drug development, by constantly refreshing their portfolio, thus preventing the loss of sales from drugs going off patent. New drugs are either developed by internal research (the majority) or through collaboration with biotech companies. The product: Davanrik Davarnik was developed by LAB Pharmaceuticals, a small and relatively young pharmaceutical concern specialized in compounds for the treatment of neurological disorders. Originally it was meat for the treatment of depression. Apart from acting on receptors involved in causing depression it also seemed to block the receptor in CNS responsible for appetite. It is currently in......

Words: 511 - Pages: 3

Identify and Evaluate Marketing Opportunities

...Assessment Materials BSBMKG501B IDENTIFY AND EVALUATE MARKETING OPPORTUNITIES To achieve competency in this unit you must complete the following assessment items. All tasks must be submitted together. Tick the boxes to show that each task is attached. * Task 1. Short answer questions ☐ * Task 2. Research report ☐ NOTE: If this is a group assignment, each member of your group must individually submit a separate and complete copy. Student ID | Student Name | Click here to enter text. | Click here to enter text. | The other members of my group are: 1. Name:Click here to enter text. Student ID#:Click here to enter text. 2. Name:Click here to enter text. Student ID#: Click here to enter text. 3. Name:Click here to enter text. Student ID#: Click here to enter text. | PLEASE NOTE: SECTIONS HIGHLIGHTED IN THIS COLOUR ARE FOR TRAINER USE TASK 1 MARKING SHEET Did the candidate | Competent | | Yes | No | Answer all questions and address all of the requirements specified in Assessment Task 1? | ☐ | ☐ | TASK 2 MARKING SHEET Did the candidate: | Competent | | Yes | No | Provide a research report and deliver a presentation to “stakeholders” addressing all of the requirements specified in Assessment Task 2? | ☐ | ☐ | | ASSESSMENT - SUMMARY | Assessor’s checklist – tick when finalized | Task 1☐ | Task 2☐ | Task 3☐ | | ASSESSOR’S GENERAL COMMENTS (see individual tasks & marking guides for more detail) | ......

Words: 1503 - Pages: 7

Merck & Company

...From the case material we can see that the value of licensing arrangement consists of three parts: Initial investment, Milestone Payment and Royalty Fee. In Phase 1, Merck has to pay LAB 5 million initial investment no matter whether Davanrik will get approved by FDA in future. In Phase 2, Merck has to pay LAB 2.5 million Milestone payment if Davanrik successfully complete Phase 1 with a probability of 60%. In Phase 3, the amount of milestone payment Merck has to pay depends on the result of Phase 2. If Davanrik successfully complete phase 2 and was effective only for depression with the probability of 10%, then Merck has to pay 20 million to LAB. If Davanrik successfully complete phase 2 and was effective only for weight loss with the probability of 15%, then Merck has to pay 10 million to LAB. If Davanrik successfully complete phase 2 and was effective for both depression and weight loss with the probability of 5%, then Merck has to pay 40 million to LAB. When finishing all three phases and getting approval by FDA, Merck has to pay Royalty fee to LAB based on the sales with 5% fee rate. After finish all three phases, there is a chance of 85% that Merck can launch Davanrik if the Phase 3 showed that it was only effective for depression and the commercialized present value is 1.2 billion. The chance decreased to 75% if Merck can only be effective for weight loss with 345 million commercialized present value. If Davanrik is effective for both, the chance of successfully......

Words: 406 - Pages: 2

Merck Company

...Should Merck license the compound? Merck would be responsible for 1) the approval of Davanrik 2) the manufacture of Danavrik 3) marketing of Danavrik Merck would pay LAB for 1) initial fee 2) royalty on all sales 3) make additional pymts as Danavrik completed each stage of approval process (3 Phases) Additional facts: approval process should take 7 years patent will cover 17 years (7 of approval process nad 10 yr period of exclusivity beginning in yr 7) 1 Assumptions: All Cash flows are expressed as after tax present values discounted to time zero, including capital expenditures At any point "failure," investment decision is to stop funding Assuming Standard deviation of 0.5 Using T= 7 years in Black-Scholes Valuation 2 Decision Tree See worksheet "Decision Tree" 3 Detailed description of Real Option Technique "First, using a decision tree, I came up with a simple expected value of $13,980,000 based on the costs to complete each phase, the probabilities of completing each phase, and the costs and probabilities associated with failure at each step in the approval process. The expected value of successful completion with Depression only was $36,390,000, for weight only $1,200,000 and for both $26,880,000. The expected value of failure (including failure at any phase) was ($59,490,000). Next, I calculated the Valuations of each successful outcome using the decision tree analysis and the spectrum of outcomes with an asymetric distribution of rewards....

Words: 1029 - Pages: 5

Merck & Company Evaluating a Drug Licensing Opportunity

...Table of Content | |Page | |1. Executive Summary…………………………………………………………… |1 | |2. Main Report…………………………………………………………………….. |2 | |3. Bibliography…………………………………………………………………….. |6 | 1. Executive Summary In 2002 the patents for the most popular drugs which generated $5.7 billion in worldwide sales would be expired. In order to anticipate the loss of sales, it is recommended to update the product portfolio by investing in the development of patented new products. LAB proposed 17 years exclusivity on Davanrik, a substance which has probability to be efficacious for depression or weight loss or both indications. Up to now LAB has completed preclinical testing and entering clinical testing. The clinical testing will take about 7 years which is divided into 3 phases. Based on the analysis given on the report, the cost on Phase I will come up to $30 million and the Phase II will be $25 million. The outcome of Phase III varies and depends on the result on Phase II. The expected outcomes are: Davanrik is 10% effective for depression only, 15% for weight loss only and 5% for both......

Words: 1007 - Pages: 5

CINTA SUCI : Suci akan punya anak kembar | Call of Duty: Ghosts | Barbora Lukesová